Key points from article :
SIRTLab Corporation, a US-based biotech company focused on longevity research, has appointed Nir Barzilai, MD, as Chief Medical Advisor and a member of the Board of Directors. The company's mission is to treat age-related diseases such as liver disease, frailty, metabolic syndrome, neurodegeneration, and inflammatory conditions.
SIRTLab was founded by Boaz Misholi and Professor Haim Cohen, who is a world leader in the research of SIRT6, a protein that's been found to significantly extend lifespan in mice.
Cohen's research has seen over $40 million in investment.
The company has patented advanced technologies to increase the activity of the SIRT6 protein.
Transgenic overexpression of SIRT6 leads to restored energy homeostasis, improved metabolic profiles, and significant prolongation of lifespan in mice.
The company has developed effective methods to increase the level of SIRT6 within body cells and expects to begin clinical trials within a year.
Nir Barzilai is, among other roles, a professor of Medicine and Genetics at Albert Einstein College of Medicine and the Director of the Paul F Glenn Center for the Biology of Human Aging Research.
Barzilai's research focuses on the biology and genetics of aging. His team has discovered functional variants of Sirt-6 in centenarians, demonstrating its relevance for humans' healthspan and lifespan.
